@misc{10481/79763,
year = {2022},
month = {12},
url = {https://hdl.handle.net/10481/79763},
abstract = {Adoptive Cell Therapy (ACT) to treat cancer represents a rapidly evolving field. New
approaches for the genetic engineering of immune effector cells with either a T cell
receptor (TCR) or a chimeric antigen receptor (CAR) (Figure 1 Panels A and B,
respectively) have led to the increase of the clinical efficacy, the reduction or better
control of toxicities and the expansion of the indications of these therapies. The Research
Topic “Engineered Immune Cells in Cancer Immunotherapy (EICCI)” represents the
venue for collecting studies, new evidence, advances in the technologies and the greatest
knowledge for the translational application on the topic of cellular therapy for cancer.
The great success of this Research Topic with the publication of total 46 articles,
including 18 original articles, 20 reviews, 5 mini reviews, 2 case reports and 1
methodology manuscript, and the contributions of 360 authors, testify to the huge
interest of the scientific community in this field and the numerous advancements.},
publisher = {Frontiers},
keywords = {Adoptive cell theraphy},
keywords = {CAR-T cells},
keywords = {TCR-engineered T cells},
keywords = {Tumor antigens},
keywords = {Mechanisms of resistance},
title = {Editorial: Engineered immune cells in cancer immunotherapy (EICCI)},
doi = {10.3389/fimmu.2022.1119363},
author = {Martín Molina, Francisco},
}